Ignite Creation Date:
2024-05-06 @ 3:25 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04629287
Status:
UNKNOWN
Last Update Posted:
2020-11-19
First Post:
2020-11-03
Brief Title:
SafetyTolerability and Pharmacokinetic of KPCXM18 for Injection
Sponsor:
Kunming Pharmaceuticals Inc
Organization:
Kunming Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Blind Placebo-controlledSingle Andmultiple Ascending Dose Study to Assess the SafetyTolerability and Pharmacokinetic of KPCXM18 for Injection in Healthy Subjects
Status:
UNKNOWN
Status Verified Date:
2020-11
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
to assess the safetyTolerability and pharmacokinetic of KPCXM18 for injection in healthy subjects
Detailed Description:
To explore the safety tolerance and pharmacokinetic of KPCXM18 for injection in healthy subjects by intravenous administration of different doses in single and multiple administration safety tolerance and pharmacokinetic tests and to obtain the safe dose range of the test drugs thus providing dose design basis for phase II clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CTR20202022 | OTHER | National Medical Products Administration | None |